Compass Therapeutics, Inc.

What they do

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Its pipeline includes tovecimig (DLL4 x VEGF-A bispecific), CTX-471 (CD137 agonist), CTX-8371 (PD-1 x PD-L1 bispecific), and CTX-10726 (PD-1 x VEGF-A bispecific). The company has no approved products and has not generated recurring revenue; it funds operations through equity offerings and has a history of net losses.

Revenue drivers

• Tovecimig (CTX-009) — Lead candidate in a Phase 2/3 trial for biliary tract cancer; reported ORR of 18.0% in the combination arm (vs. 5.3% for paclitaxel alone) in final analysis; plans to file a BLA later in 2026.
• CTX-8371 — PD-1 x PD-L1 bispecific in Phase 1 cohort expansions for triple-negative breast cancer, non-small cell lung cancer, and Hodgkin lymphoma; selected based on durable responses in dose escalation.
• CTX-471 — CD137 agonist antibody; Phase 1 showed monotherapy activity in post-PD-1/PD-L1 patients; Phase 2 basket study in NCAM+ tumors expected to initiate in Q3 2026.
• CTX-10726 — PD-1 x VEGF-A bispecific; Phase 1 study initiated with first patients dosed; initial data expected in Q4 2026.

Recent performance

For Q2 2026, the company reported cash and marketable securities of $180 million. Net loss for 2025 was $66.5 million, with annual operating cash outflow of $49.1 million. Revenue was zero in 2025 and in most recent quarters, except a one-time $850,000 in Q2 2024. The tovecimig Phase 2/3 trial met its primary endpoint with an ORR of 18.0% (vs. 5.3% for paclitaxel; p=0.0228), and the company expects FDA feedback in Q3 2026 before a potential BLA filing.

Strategy

Compass is prioritizing tovecimig's BLA submission for biliary tract cancer, while expanding into earlier lines and additional solid tumor indications (e.g., colorectal cancer) via investigator-sponsored trials. The company is developing a broader pipeline of bispecific and agonist antibodies as standalones and combinations, including CTX-8371 cohort expansions and CTX-10726 Phase 1 dosing. Management expects to provide FDA feedback shortly, with additional clinical data presentations at ESMO and other conferences in late 2026.

Risks

• No approved products — The company has no commercial products and expects significant losses for the foreseeable future; may never achieve profitability.
• Clinical regulatory risk for tovecimig — FDA feedback expected in Q3 2026 may not be favorable, and a BLA filing could be delayed or rejected.
• Capital burn and dilution — With $180 million in cash and marketable securities expected to fund operations into 2028, continued losses could require additional equity financing, diluting shareholders.
• Early-stage pipeline setbacks — CTX-8371, CTX-471, and CTX-10726 are in early-stage trials; clinical data may not support further development or registration.

Outlook

Management expects to receive FDA feedback on tovecimig in Q3 2026, with a potential BLA filing later this year. CTX-471 Phase 2 basket study will initiate in Q3, CTX-10726 Phase 1 data are expected in Q4, and CTX-8371 cohort expansions are enrolling. The company anticipates a series of meaningful updates in the remainder of 2026. Cash and marketable securities of $180 million are expected to fund operations into 2028.